Dan Martin: And Tyler, this is Dan Martin. I’ll take your question on what gives us confidence in the TGCT market. I think what gives us confidence is several factors. First, you mentioned the claims analysis that we’ve presented on. That was just a component of our overall analysis of the opportunity. We actually conducted a couple of different methodologies, all of which gave very similar answers. We conducted a more typical sort of literature-based epi build up and totally separately, we conducted the claims analysis, and both resulted in a really similar findings in terms of the overall patient journey for TGCT as well as the size of the addressable opportunity. We €“ as it relates to the claims data, the 1,300 to 1,400 patients that we have noted as being the incident Rx-treated patients in the U.S. in this data set, we’ve always viewed that as really a floor of the opportunity and one that gives us real confidence because this is an analysis that doesn’t provide indicators of patients, it actually sees the patients.
And so we can see these patients being treated in the data, which gives us great confidence. Lastly, I would just note that one of the things that we get asked is our view of sort of products used in the space and market share, and we’ve presented the findings from the claims database there as well showing that only about 15% of the patients received pexidartinib in this data set. And that enables us to sort of triangulate or crosswalk back to the opportunity that we’ve laid out. So across multiple different views of the market we land in very similar places which gives us great confidence that the opportunity is there. Lastly, I’ll just note that diffuse markets with patients being spread between both academic and community settings as a bit of a specialty of ours.
We’ve developed real capability and being successful in that space because that’s very much the description of GIST. GIST is very similar in that way. And frankly, one more point is that we know that the overlap between GIST and TGCT is really high. So for all these reasons, we have great confidence that the market is there and that we’re uniquely positioned to be successful.
Tyler Van Buren: Thank you very much.
Operator: Please stand by for our next question. Our next question comes from Eun Yang with Jefferies. Your line is now open.
Eun Yang: Thank you. I have actually a few questions. First, you mentioned that in 2022, the treatment duration for QINLOCK was 7 months and expect that to increase to 8.5 months. What’s driving the increase in the treatment of duration? And do you expect to achieve 8 to 8.5 months of this year? Second question is on the NCCN guidelines. I don’t know, it’s something €“ I understand it is something that we cannot predict. But you have submitted your data for second-line INTRIGUE data. But in light of the subgroup analysis in Exon 11, 17 and 18 patient population, do you expect the NCCN decision could be on that subgroup? Thank you.
Steve Hoerter: Yes. Hi, good morning. Eun. Thanks for the great questions. So I’ll take the second question first with respect to NCCN, and then I’ll ask Dan to cover off on the treatment duration for QINLOCK that we see in the real-world experience in the U.S. market. So first for NCCN, you’re exactly right, Eun. It’s not something that we can predict in terms of whether the NCCN is going to update the guidelines when that might occur or what might be reflected in the guideline update. We were excited to present the data from the subgroup as part of the ASCO Plenary Series Session just last month, very compelling data in this group of patients with QINLOCK. So we’re excited about that. I think the field is very excited about it as you will have seen from the presentation and the discussion at the ASCO session at the end of January.
